EU to slap big fine on French drugmaker Servier: sources

The EU is expected to inflict a heavy fine in the coming days on French drugs giant Servier for colluding to delay a cheaper version of a popular blood-pressure treatment, sources close to the matter told AFP on Tuesday.

The European Commission will decide on the fine before the end of the month, the sources said. Israeli generic giant Teva and three other companies are also involved in the case.

Servier is suspected of trying to delay the of perindopril, a cardio-vascular medicine. The allegation is the result of a broad EU probe into the pharmaceutical industry launched in 2008.

Generic products are far cheaper than brand medicines—on average generics cost 40 percent less two years after they enter the market—and are a huge savings to patients and while remaining just as effective.

In so-called pay-for-delay deals, drug makers pay generic rivals to thwart the introduction of cheaper versions of blockbuster drugs for an agreed time.

If Servier is found guilty in the collusion it faces heavy fines of up to 10 percent of the group's total annual sales.

A year ago, Danish drugmaker Lundbeck was fined 93.8 million euros by the Commission for striking a 2002 agreement to delay the generic version of its popular anti-depressant, citalopram.

add to favorites email to friend print save as pdf

Related Stories

EU fines pharma firms over generics delay (Update)

Jun 19, 2013

(AP)—The European Union has fined Danish pharmaceuticals multinational Lundbeck and several other producers a combined 146 million euros ($195 million) for delaying the market entry of cheaper generic alternatives ...

Pfizer, Teva reach deal to allow generic Viagra

Dec 17, 2013

Pfizer says it reached a settlement with Teva Pharmaceuticals that allows the generic drugmaker to launch a copycat version of its popular erectile dysfunction drug Viagra in 2017.

High court weighs drug companies' generics policy

Mar 25, 2013

(AP)—The Supreme Court is struggling with whether it should stop pharmaceutical corporations from paying generic drug competitors to delay releasing their cheaper versions of brand-name drugs.

US: 'Pay to delay' generic drugs can be illegal (Update)

Jun 17, 2013

The Supreme Court ruled Monday that deals between pharmaceutical corporations and their generic drug competitors, which government officials say keep cheaper forms of medicine off the market, can be sometimes be illegal and ...

FDA approves generic version of celebrex

Jun 03, 2014

(HealthDay)—The U.S. Food and Drug Administration on Friday gave its approval to the first generic version of the pain reliever Celebrex (celecoxib).

Recommended for you

Drug research and development more efficient than expected

Feb 27, 2015

Drug R&D costs have increased substantially in recent decades, while the number of new drugs has remained fairly constant, leading to concerns about the sustainability of drug R&D and question about the factors that could ...

Use new meningitis vaccines only for outbreaks

Feb 26, 2015

(AP)—A U.S. panel on Thursday recommended that two new meningitis vaccines only be used for rare outbreaks, resisting tearful pleas to give it routinely to teens and college students.

New antibiotic avycaz approved

Feb 26, 2015

(HealthDay)—The combination antibiotic Avycaz (ceftazidime-avibactam) has been approved by the U.S. Food and Drug Administration to treat adults with complicated infections of the intra-abdominal area or urinary tract, ...

Tagging drugs to fight counterfeit medicines

Feb 25, 2015

The U.S. and other countries are enacting rules to clamp down on the sales of fake pharmaceuticals, which pose a public health threat. But figuring out a system to track and authenticate legitimate drugs still faces significant ...

User comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.